What's ahead for COVID-19 drugs and vaccines in 2021
- The 10 big events to pay attention to when it comes to COVID-19 vaccines and treatments;
- We broke down where the top biotechs (according to VCs) are based;
- Find out why One Medical made its $1.4 billion bet on Iora.
If you're new to this newsletter, sign up here. Tips, comments? Email me at firstname.lastname@example.org or tweet @lydiaramsey125. Let's get to it...
As you might expect, there'll be no newsletter Monday. Have a great long weekend, and see you Tuesday!
What's next for vaccines and treatments
Following Pfizer's vaccine approval, there's still more to come as drugmakers look to get
Andrew Dunn rounded up 10 newsworthy moments to keep an eye out for in the remainder of 2021.
They include updates on new antiviral treatments as well as when we might get shots authorized for kids 12 and under.
Here's what to expect>>
Vaccines for kids, game-changing treatments, and the fate of booster shots: Here are the top 10 COVID-19 events to watch for in 2021
Top biotechs on either coast
Investors this summer picked out biotechs they think are set to take off in the next year.
For those closely following the
Andrew and Allison DeAngelis have the bicoastal lists up this week.
Check it out>>
6 of the top Boston-area biotech upstarts that VCs say are poised to take off in the next 12 months
9 top Bay Area biotechs that VCs say are poised to take off in the next year
Inside the One Medical-Iora deal
The $1.4 billion One Medical-Iora deal closed on Wednesday.
Mohana Ravindranath spoke to the leaders of the two (now one) companies to learn more about the decision to combine the primary care organizations.
The thinking: One Medical wants to treat people when they're young, but also when they age into Medicare at 65.
"If we're going to try to attract you, how about your parents or your grandparents? Or if you have kids, your kids. We're speaking across a common brand, and ultimately across common technology platforms," One Medical CEO Amir Rubin told us.
Read more from the interview>>
One Medical is making a $1.4 billion bet on eldercare pioneer Iora. CEO Amir Rubin tells us why.
More stories that kept us busy this week:
- Be sure to check out this piece on the steps people are taking to get IUDs removed.
- The jury's been selected for Theranos founder Elizabeth Holmes' trial. Catch up on everything you need to know heading into the trial here.
- Psychedelics companies are acting like biotechs. So maybe it shouldn't be a big surprise that some top biotech VCs are getting on board. Yeji Jesse Lee has the story of $1.1 billion psychedelics company GH Research, which has drawn backing from top healthcare investors.
- A 'hole' 30 times Earth's size has spread across the sun, blasting solar winds that'll hit our planet by end of this week
- Durjoy Datta tweets about Paytm UPI LITE making payments faster and easier, fellow author Ravinder Singh responds
- A former Twitter engineer said they watched colleagues 'drop like flies' from a virtual meeting during Elon Musk's mass layoffs
- Best water purifiers to buy in India 2023
- Desk-bombing, monk mode & other emerging trends at the workplace
- Crypto exchange Binance temporarily suspends all spot trading
- Samsung unveils Galaxy F14 5G with 6000 mAh battery in India
- Haircut on cases resolved through IBC not very encouraging, says Kotak report